Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Fate Therapeutics cash
Cash and short-term investments held at the end of each period.
Fate Therapeutics's cash was $139.10M at Sep 30, 2026. For fiscal 2025 it was $203.66M, down 27.0% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $615.91M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.66M | -27.0% |
| FY2024 | Dec 31, 2024 | $279.07M | -11.5% |
| FY2023 | Dec 31, 2023 | $315.18M | -27.7% |
| FY2022 | Dec 31, 2022 | $436.23M | -29.2% |
| FY2021 | Dec 31, 2021 | $615.91M | +268.0% |
| FY2020 | Dec 31, 2020 | $167.35M | +67.7% |
| FY2019 | Dec 31, 2019 | $99.81M | -47.6% |
| FY2018 | Dec 31, 2018 | $190.51M | +114.2% |
| FY2017 | Dec 31, 2017 | $88.95M | -3.4% |
| FY2016 | Dec 31, 2016 | $92.11M | +42.1% |
| FY2015 | Dec 31, 2015 | $64.81M | +31.7% |
| FY2014 | Dec 31, 2014 | $49.22M | -8.9% |
| FY2013 | Dec 31, 2013 | $54.04M | +494.7% |
| FY2012 | Dec 31, 2012 | $9.09M | +42.3% |
| FY2011 | Dec 31, 2011 | $6.39M | -43.1% |
| FY2010 | Dec 31, 2010 | $11.23M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $139.10M | -35.4% |
| Q2 FY2026 | Jun 30, 2026 | $153.80M | -31.0% |
| Q1 FY2026 | Mar 31, 2026 | $174.80M | -27.3% |
| Q4 FY2025 | Dec 31, 2025 | $203.66M | -27.0% |
| Q3 FY2025 | Sep 30, 2025 | $215.42M | -27.4% |
| Q2 FY2025 | Jun 30, 2025 | $222.83M | -26.9% |
| Q1 FY2025 | Mar 31, 2025 | $240.43M | +98.2% |
| Q4 FY2024 | Dec 31, 2024 | $279.07M | -11.5% |
| Q3 FY2024 | Sep 30, 2024 | $296.92M | +790.8% |
| Q2 FY2024 | Jun 30, 2024 | $304.88M | +551.4% |
| Q1 FY2024 | Mar 31, 2024 | $121.32M | +188.7% |
| Q4 FY2023 | Dec 31, 2023 | $315.18M | -27.7% |
| Q3 FY2023 | Sep 30, 2023 | $33.33M | -59.4% |
| Q2 FY2023 | Jun 30, 2023 | $46.80M | -15.3% |
| Q1 FY2023 | Mar 31, 2023 | $42.02M | -35.1% |
| Q4 FY2022 | Dec 31, 2022 | $436.23M | -29.2% |
| Q3 FY2022 | Sep 30, 2022 | $82.09M | -36.5% |
| Q2 FY2022 | Jun 30, 2022 | $55.28M | -27.9% |
| Q1 FY2022 | Mar 31, 2022 | $64.74M | -39.2% |
| Q4 FY2021 | Dec 31, 2021 | $615.91M | +268.0% |
| Q3 FY2021 | Sep 30, 2021 | $129.18M | -63.0% |
| Q2 FY2021 | Jun 30, 2021 | $76.65M | -82.3% |
| Q1 FY2021 | Mar 31, 2021 | $106.41M | +27.6% |
| Q4 FY2020 | Dec 31, 2020 | $167.35M | +67.7% |
| Q3 FY2020 | Sep 30, 2020 | $349.13M | +39.9% |
| Q2 FY2020 | Jun 30, 2020 | $433.07M | +506.2% |
| Q1 FY2020 | Mar 31, 2020 | $83.37M | -54.5% |
| Q4 FY2019 | Dec 31, 2019 | $99.81M | -47.6% |
| Q3 FY2019 | Sep 30, 2019 | $249.59M | +36.2% |
| Q2 FY2019 | Jun 30, 2019 | $71.44M | +97.5% |
| Q1 FY2019 | Mar 31, 2019 | $183.03M | +456.1% |
| Q4 FY2018 | Dec 31, 2018 | $190.51M | +114.2% |
| Q3 FY2018 | Sep 30, 2018 | $183.25M | +323.9% |
| Q2 FY2018 | Jun 30, 2018 | $36.16M | -49.1% |
| Q1 FY2018 | Mar 31, 2018 | $32.91M | -60.1% |
| Q4 FY2017 | Dec 31, 2017 | $88.95M | -3.4% |
| Q3 FY2017 | Sep 30, 2017 | $43.23M | – |
| Q2 FY2017 | Jun 30, 2017 | $71.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $82.42M | – |
| Q4 FY2016 | Dec 31, 2016 | $92.11M | – |
See a number that looks wrong?